Description
Zinnat 250Mg/5Ml Suspension 50 Ml
Description :
Cefuroxime (as axetil) (Zinnat) 250 mg Tablet: Each tablet contains 250 mg of Cefuroxime (as axetil).
Cefuroxime (as axetil) (Zinnat) 500 mg Tablet: Each tablet contains 500 mg of Cefuroxime (as axetil).
Cefuroxime (as axetil) (Zinnat) 125 mg/5 mL Granules for Suspension: Each contains 125 mg Cefuroxime (as axetil) per teaspoon (5 mL) of suspension.
Cefuroxime (as axetil) (Zinnat) 250 mg/5 mL Granules for Suspension: Each contains 250 mg Cefuroxime (as axetil) per teaspoon (5 mL) of suspension.
Sachet: Cefuroxime (as axetil) (Zinnat) 125 mg Granules for Suspension: Each 4.22 g of single-use sachet contains 125 mg Cefuroxime (as axetil).
Indications / Uses :
Cefuroxime axetil (Zinnat) is an oral prodrug of the bactericidal cephalosporin antibiotic cefuroxime, which is resistant to most ? (beta)-lactamases and is active against a wide range of Gram-positive and Gram-negative organisms.
It is indicated for the treatment of infections caused by susceptible bacteria.
Susceptibility to Cefuroxime axetil (Zinnat) will vary with geography and time and local susceptibility data should be consulted where available (see Pharmacology: Pharmacodynamics under Actions).
Indications include: Upper respiratory tract infections for example, ear, nose and throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis; lower respiratory tract infections for example, pneumonia, acute bronchitis, and acute exacerbations of chronic bronchitis; genito-urinary tract infections for example, pyelonephritis, cystitis and urethritis; skin and soft tissue infections for example, furunculosis, pyoderma and impetigo; gonorrhoea, acute uncomplicated gonococcal urethritis, and cervicitis; treatment of early Lyme disease and subsequent prevention of late Lyme disease in adults and children over 12 years old.
Cefuroxime is also available as the sodium salt (Zinacef) for parenteral administration. This permits the use of sequential therapy with the same antibiotic, when a change from parenteral to oral therapy is clinically indicated.
Where appropriate Cefuroxime axetil (Zinnat) is effective when used following initial parenteral cefuroxime sodium (Zinacef) in the treatment of pneumonia and acute exacerbations of chronic bronchitis.
Administration :
Should be taken with food: Take immediately after food.
Contraindications :
Patients with known hypersensitivity to cephalosporin antibiotics.
Special Precautions :
Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactams.
As with other antibiotics, use of Cefuroxime axetil (Zinnat) may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of other non-susceptible organisms (e.g. enterococci and Clostridium difficile), which may require interruption of treatment.
Pseudomembranous colitis has been reported with the use of antibiotics, and may range in severity from mild to life-threatening.
Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. If prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.
Tablet: The Jarisch-Herxheimer reaction has been seen following Cefuroxime axetil (Zinnat) treatment of Lyme disease. It results directly from the bactericidal activity of Cefuroxime axetil (Zinnat) on the causative organism of Lyme disease, the spirochaete Borrelia burgdorferi. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease.
With a sequential therapy regime the timing of change to oral therapy is determined by severity of the infection, clinical status of the patient and susceptibility of the pathogens involved. If there is no clinical improvement within 72 hours, then the parenteral course of treatment must be continued.
Please refer to the relevant prescribing information for cefuroxime sodium before initiating sequential therapy.
Suspension: The sucrose content of Cefuroxime axetil (Zinnat) suspension and granules should be taken into account when treating diabetic patients, and appropriate advice provided.
Cefuroxime axetil (Zinnat) suspension contains aspartame, which is a source of phenylalanine and so should be used with caution in patients with phenylketonuria.
Ability to Perform Tasks that Require Judgement, Motor or Cognitive Skills: As this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.
Reviews
There are no reviews yet.